Pharmafile Logo

molgramostim neubuliszer solution

- PMLiVE

Savara announces positive phase 3 results for molgramostim in rare lung disease

Autoimmune pulmonary alveolar proteinosis affects around one in every 150,000 people in the US

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links